Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years

benzinga.com/news/health-care/25/05/45700729/roches-multiple-sclerosis-drug-shows-low-disease-activity-over-two-years

Roche Holdings AG (OTC:RHHBY) on Friday announced new 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability progression and low disease activity levels for up to two years.
The latest results for this investigational…

This story appeared on benzinga.com, 2025-05-30 17:17:57.
The Entire Business World on a Single Page. Free to Use →